COMBINATION INCLUDING AT LEAST ONE SPLICEOSOME MODULATOR AND AT LEAST ONE INHIBITOR SELECTED FROM BCL2 INHIBITORS, BCL2/BCLXL INHIBITORS, AND BCLXL INHIBITORS, AS WELL AS APPLICATION METHODS Russian patent published in 2022 - IPC A61K45/00 A61K31/105 A61K31/11 A61K31/166 A61K31/343 A61K31/352 A61K31/426 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely to a pharmaceutical composition including: (i) therapeutically effective amount of at least one spliceosome modulator selected from E7107, H3B-8800, and their pharmaceutically acceptable salts, and (ii) therapeutically effective amount of at least one inhibitor selected from venetoclax (ABT199), navitoclax (ABT263), A-1331852, and their pharmaceutically acceptable salts. The group of inventions also relates to a combination for the treatment of a malignant tumor selected from hemoblastoses and solid tumors, including: (i) at least one spliceosome modulator selected from E7107, H3B-8800, and their pharmaceutically acceptable salts, and (ii) at least one inhibitor selected from venetoclax (ABT199), navitoclax (ABT263), A-1331852, and their pharmaceutically acceptable salts. In this case, at least one spliceosome modulator is administered simultaneously, separately, or sequentially with at least one inhibitor. The group of inventions also relates to the use of a combination including: (i) at least one spliceosome modulator selected from E7107, H3B-8800, and their pharmaceutically acceptable salts, and (ii) at least one inhibitor selected from venetoclax (ABT199), navitoclax (ABT263), A-1331852, and their pharmaceutically acceptable salts, for the treatment of a malignant tumor selected from hemoblastoses and solid tumors. In this case, at least one spliceosome modulator is administered simultaneously, separately, or sequentially with at least one inhibitor. The group of inventions also relates to a method for the treatment of a malignant tumor, including the administration to a subject who needs it of: (i) therapeutically effective amount of at least one spliceosome modulator selected from E7107, H3B-8800, and their pharmaceutically acceptable salts, and (ii) therapeutically effective amount of at least one inhibitor selected from venetoclax (ABT199), navitoclax (ABT263), A-1331852, and their pharmaceutically acceptable salts, where the malignant tumor is selected from hemoblastoses and solid tumors. In this case, at least one spliceosome modulator is administered simultaneously, separately, or sequentially with at least one inhibitor.

EFFECT: group of inventions provides a synergetic antitumor effect of combinations of spliceosome modulators and inhibitors.

84 cl, 14 dwg